Literature DB >> 11434611

Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy.

A Douglass1, H Al Mardini, C Record.   

Abstract

BACKGROUND/AIMS: To mimic episodic hepatic encephalopathy after gastrointestinal bleeding under controlled conditions, cirrhotic patients were challenged with an amino acid mixture of comparable composition to haemoglobin.
METHODS: Basal EEG, psychometric score (HE test), reaction times and venous blood ammonia were recorded. Following a 54 or 108 gm oral amino acid challenge, blood ammonia levels and EEG were recorded at 30-min intervals, and psychometric testing was repeated at 180 min. Ten controls (57 +/- 2) and 31 cirrhotics (52 +/- 2) of which 21 were Child's grade A or B and 10 grade C underwent the challenge. Nine had a transjugular intrahepatic porta-systemic shunt in situ.
RESULTS: Seventeen patients had abnormal baseline HE scores. Basal blood ammonia and reaction time A were significantly greater in patients (52 +/- 5 micromol/l and 478 +/- 20 ms, respectively) than controls (19 +/- 2 micromol/l and 372 +/- 14 ms) (P < 0.001). Following the challenge, in patients with advanced liver disease (Child's grade B and C) the slowing of reaction time A (+85 +/- 38 and +71 +/- 31 ms, respectively; P < 0.03) and EEG (ratio of slow to fast wave activity +0.31 +/- 0.12 and +0.58 +/- 0.19; P < 0.02) were significantly greater than in controls (-3.3 +/- 8 ms and 0.00 +/- 0.03, respectively). Patients with an abnormal basal HE score had the most pronounced changes (reaction time A +110 +/- 39 ms, P < 0.01, EEG +0.52 +/- 13, P < 0.01, respectively). The change in EEG ratio correlated with the dose of amino acid administered (r = 0.96; P < 0.008).
CONCLUSION: The amino acid challenge constitutes a reproducible human model of episodic, Type C hepatic encephalopathy unaffected by the complications usually encountered in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11434611     DOI: 10.1016/s0168-8278(01)00004-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

2.  Role of ammonia and inflammation in minimal hepatic encephalopathy.

Authors:  D L Shawcross; G Wright; S W M Olde Damink; R Jalan
Journal:  Metab Brain Dis       Date:  2007-03       Impact factor: 3.584

3.  Amino acid challenge in patients with cirrhosis and control subjects: ammonia, plasma amino acid and EEG changes.

Authors:  Hanan Al Mardini; Andrew Douglass; Christopher Record
Journal:  Metab Brain Dis       Date:  2006-05-04       Impact factor: 3.584

4.  Absence of neuropsychological impairment in hyperammonaemia in healthy young adults; possible synergism in development of hepatic encephalopathy (HE) symptoms?

Authors:  Daniel J Wilkinson; Nicholas J Smeeton; Paul C Castle; Peter W Watt
Journal:  Metab Brain Dis       Date:  2011-07-20       Impact factor: 3.584

5.  Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.

Authors:  Maria Garrido; Jelena Skorucak; Daniela Raduazzo; Matteo Turco; Giuseppe Spinelli; Paolo Angeli; Piero Amodio; Peter Achermann; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2016-05-19       Impact factor: 3.584

6.  Oral tryptophan challenge studies in cirrhotic patients: no evidence of neuropsychiatric changes.

Authors:  Andrew Douglass; Hanan Al Mardini; Christopher O Record
Journal:  Metab Brain Dis       Date:  2003-09       Impact factor: 3.584

7.  Acute hyperammonaemia induces a sustained decrease in vigilance, which is modulated by caffeine.

Authors:  E P Casula; P S Bisiacchi; M Corrias; S Schiff; C Merkel; P Amodio; S Montagnese
Journal:  Metab Brain Dis       Date:  2014-07-24       Impact factor: 3.584

Review 8.  Therapeutic studies in hepatic encephalopathy.

Authors:  Kevin D Mullen; Piero Amodio; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

9.  Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy.

Authors:  Marco Senzolo; Lisa Zarantonello; Chiara Formentin; Costanza Orlando; Raffaello Beltrame; Anna Vuerich; Paolo Angeli; Patrizia Burra; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2019-09-10       Impact factor: 3.584

Review 10.  Pathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in man.

Authors:  Hanan Mardini; Christopher Record
Journal:  Metab Brain Dis       Date:  2012-11-23       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.